EGFR and cancer: Anti-EGFR monoclonal antibodies conjugated MR contrast, F-18 labeled Affibody protein, C-11 erlotinib, Lu-177 nimotuzumab, or C-11 labeled 4-N-(3-bromoanilino)-6, 7-dimethoxyquinazoline, have been developed to target the EGFR of cancer [6–9].